NANTONG, China, April 8 /PRNewswire-FirstCall/ -- Sinobiopharma Pharmaceutical Group (BULLETIN BOARD: SNBP) is pleased to announce the appointment of Ms. Yan Tan as Director of Marketing.
Ms. Tan joins Sinobiopharma from Organon Pharmaceutical Co., Ltd., Netherlands. She served as a China-based Unit Marketing Director for Organon, which was recently sold to Schering-Plough. Prior to Organon, Ms. Tan held senior marketing management roles at China National Medicines Corporation Ltd.
"We are delighted to welcome Ms. Tan to our team," said Lequn Huang, Chairman and CEO of Sinobiopharma. "Ms. Tan's valuable experience in marketing and sales from global healthcare and consumer businesses will bring additional marketing expertise to the company's sales and marketing strategy. I am confident that she will help us grow our business both domestically and internationally with specific initial focus on increasing sales to hospitals and pharmacies across China."
About Sinobiopharma
Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.
FORWARD LOOKING STATEMENTS
This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward looking statement, except as required under applicable law.
Sinobiopharma, Inc.
CONTACT: Sinobiopharma, Inc., Investor Relations, 1-877-568-0188
Web Site: http://www.sinobiopharma.com/
